SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice.

Authors:
Pavan MF; Bok M; Betanzos San Juan R; Malito JP; Marcoppido GA and 13 more

Journal:
Viruses

Publication Year: 2024

DOI:
10.3390/v16020185

PMCID:
PMC10892724

PMID:
38399961

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Viruses

Abbreviation: Viruses

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Virology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
AC-73 and Syrosingopine Inhibit SARS-CoV-2 Entry into Megakaryocytes by Targeting CD147 and MCT4.
Spinello I; Saulle E; Quaranta MT and 7 more (2024) - Transparency Score: 3/6
A Canadian Survey of Research on HIV-1 Latency-Where Are We Now and Where Are We Heading?
Abdalla AL; Guajardo-Contreras G; Mouland AJ. (2024) - Transparency Score: 3/6
Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeuti…
Chanda D; Del Rivero T; Ghimire R and 4 more (2024) - Transparency Score: 3/6
Active Surveillance of Powassan Virus in Massachusetts <i>Ixodes scapularis</i> Ticks, Comparing De…
Xu G; Siegel E; Fernandez N and 5 more (2024) - Transparency Score: 3/6
Antiviral Defence Mechanisms during Early Mammalian Development.
Mueller F; Witteveldt J; Macias S. (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interest The authors declare no conflicts of interest."

Evidence found in paper:

"This study was supported by the Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (ANPCyT) IP-COVID-19-406 “Development and production of critical reagents for diagnosis and treatment of COVID-19: Nanobodies, polyclonal IgY antibodies, and recombinant proteins” to VP and LII. This work was also partially supported by a grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award Number R01AI153433 to AJA and COVID Rapid Response Fund from Virginia Tech to LY and AJA. KL is supported by a Gilliam Fellowship for Advanced Study from the Howard Hughes Medical Institute."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025